[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"high-risk-pregnancy\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:high-risk-pregnancy":99},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,12,0,[8,52,85,113,140,190,212,239,266,300,323,350],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":4,"eligibilityCriteria":15,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":18,"targetDuration":4,"studyType":21,"phases":22,"briefSummary":24,"conditions":25,"keywords":29,"overallStatus":40,"whyStopped":4,"lastUpdateSubmitDate":41,"lastUpdatePostDateStruct":42,"startDateStruct":45,"completionDateStruct":47,"leadSponsor":49,"locationsCount":4},"100635929","effects-of-emotional-freedom-technique-and-music-therapy-in-high-risk-pregnancy-100635929",false,"NCT07559071","Effects of Emotional Freedom Technique and Music Therapy in High-Risk Pregnancy","The Effect of Emotional Freedom Technique and Music Therapy Applied to High-Risk Pregnant Women on Maternal Psychological Status, Coping Methods, and Non-Stress Test Findings: A Randomized Controlled Trial","Inclusion Criteria:\n\n* Women aged 18 years and older\n* Able to speak and understand Turkish\n* Diagnosed with preterm premature rupture of membranes (PPROM)\n* Gestational age between 28+0 and 35+5 weeks\n* Score of ≥1 on the Subjective Units of Disturbance Scale (SUDS)\n* Singleton pregnancy\n* Able and willing to communicate and participate in the study\n\nExclusion Criteria:\n\n* Pregnancy achieved via assisted reproductive technologies\n* Presence of any obstetric complication other than PPROM\n* Presence of major fetal anomalies\n* Active labor at the time of recruitment\n* Hearing impairment\n* Presence of infection, wounds, or scars at tapping sites (for EFT application)\n* History of severe psychiatric disorder or currently receiving psychiatric treatment\n* Any maternal or fetal condition requiring emergency medical intervention","FEMALE","18 Years",{"count":19,"type":20},177,"ESTIMATED","INTERVENTIONAL",[23],"NA","Pregnancy is a physiological process; however, it is also a dynamic period during which obstetric and medical complications that may threaten maternal and fetal health can occur. In the presence of such complications, pregnancy is defined as a high-risk pregnancy, accounting for approximately 10-20% of all pregnancies. Due to the increased risk of maternal and fetal morbidity and mortality, high-risk pregnancies are considered a significant public health issue.\n\nAmong high-risk pregnancies, premature rupture of membranes (PROM) and particularly preterm premature rupture of membranes (PPROM) are obstetric conditions associated with serious risks for maternal and perinatal outcomes. PPROM is responsible for a substantial proportion of preterm births and is associated with an increased risk of neonatal complications.\n\nDuring the course of PROM and PPROM, the latency period between membrane rupture and delivery constitutes a significant source of uncertainty and psychosocial burden for pregnant women. Factors such as prolonged hospitalization, risk of complications, and fear of fetal loss may lead to increased levels of stress, anxiety, and depression in this population.\n\nIn the face of intense stress and uncertainty, coping strategies emerge as an important determinant of psychological outcomes. Coping refers to the cognitive and behavioral efforts individuals employ to manage situations perceived as threatening and is generally classified into active and avoidant coping strategies. Avoidant coping strategies have been associated with higher levels of anxiety and depression, whereas adaptive coping strategies are reported to enhance psychological resilience.\n\nMaternal psychological status may influence not only the mother's mental health but also fetal well-being. In this context, the non-stress test (NST) is an important tool for evaluating fetal autonomic nervous system function and allows monitoring of the relationship between maternal psychological status and fetal physiological responses. However, findings regarding the relationship between maternal anxiety and depression and NST parameters remain inconsistent.\n\nCurrent clinical management of PROM and PPROM primarily focuses on preventing obstetric complications, while the maternal psychological dimension often remains secondary. Therefore, safe and feasible non-pharmacological interventions during pregnancy have gained increasing attention.\n\nEmotional Freedom Technique (EFT) and music therapy are among the non-pharmacological interventions shown to be effective in reducing stress, anxiety, and depression during pregnancy. However, no studies have been identified in the literature evaluating the effects of these interventions on maternal psychological status, coping strategies, and fetal well-being in high-risk pregnancy groups such as PROM and PPROM. Therefore, randomized controlled trials are needed to evaluate the effects of EFT and music therapy on maternal psychological status, coping strategies, and fetal well-being in pregnant women diagnosed with PPROM.",[26,27,28],"Preterm Premature Rupture of Membranes (PPROM)","Premature Rupture of Membranes (PROM)","High-Risk Pregnancy",[30,31,28,32,33,34,35,36,37,38,39],"Emotional Freedom Technique","Music Therapy","PPROM","Maternal Mental Health","Anxiety","Depression","Stress","Coping Strategies","Non-Stress Test","Fetal Well-Being","NOT_YET_RECRUITING","2026-04-26",{"date":43,"type":44},"2026-04-30","ACTUAL",{"date":46,"type":20},"2026-06-01",{"date":48,"type":20},"2027-03",{"name":50,"class":51},"Selcuk University","OTHER",{"id":53,"slug":54,"hasResults":11,"nctId":55,"briefTitle":56,"officialTitle":57,"acronym":4,"eligibilityCriteria":58,"healthyVolunteers":59,"sex":16,"minAge":17,"maxAge":60,"enrollmentInfo":61,"targetDuration":4,"studyType":21,"phases":63,"briefSummary":64,"conditions":65,"keywords":67,"overallStatus":74,"whyStopped":4,"lastUpdateSubmitDate":75,"lastUpdatePostDateStruct":76,"startDateStruct":78,"completionDateStruct":80,"leadSponsor":82,"locationsCount":84},"100587735","leg-heating-in-pregnant-women-with-obesity-100587735","NCT06932250","Leg Heating in Pregnant Women With Obesity","Vascular and Neural Mechanisms of Chronic Leg Heating in Pregnant Women With Obesity","Inclusion Criteria:\n\n* Women with overweight or obesity (self-reported pre-pregnancy body mass index ≥25 kg\u002Fm2) between 10-14 weeks of gestation and aged 18-45 years old will be enrolled.\n* Both normotensive and hypertensive (office sitting systolic BP 140-150 mmHg and\u002For diastolic BP 90-100 mmHg) pregnant women will be enrolled if they are not on any antihypertensive drug treatment.\n* We will enroll both nulliparous and multiparous women.\n* There is no restriction regarding race\u002Fethnicity and socioeconomic status.\n* Women with a history of HDP will be allowed to participate.\n* Women taking low-dose aspirin will be allowed to participate and aspirin use will be documented.\n\nExclusion Criteria:\n\n* Current multiple pregnancies (e.g., twins, triplets, etc.).\n* Known major fetal chromosomal or anatomical abnormalities diagnosed during the study.\n* Recurrent miscarriage (three or more, to avoid antiphospholipid antibody syndrome).\n* Office sitting BP \\\u003C100\u002F55 mmHg or \\>150\u002F100 mmHg (for safety reasons).\n* Evidence of cardiovascular, pulmonary, or neurological diseases.\n* Diabetes mellitus (to avoid its effects on vascular endothelial function and sympathetic vasoconstriction).\n* Kidney disease (serum creatinine \\>0.9 mg\u002FdL).\n* Clinical known deep vein thrombosis, clinical symptoms and history of deep vein thrombosis, or dermatological lesions.\n* History of drug or alcohol abuse within the last 2 years.\n* Current tobacco use.\n* Pregnant women who do not have air conditioning at home during summer (for safety reasons).",true,"45 Years",{"count":62,"type":20},118,[23],"Obesity is a major risk factor for hypertensive disorders of pregnancy (HDP). The underlying mechanisms are largely unclear, but maternal vascular endothelial dysfunction is likely involved. Endothelial dysfunction in HDP could be attributed to 1) alterations in the L-arginine\u002Fnitric oxide (NO) pathway, and 2) an increase in endothelin-1 (ET-1). Additionally, augmented sympathetic vasoconstriction may also contribute to HDP. Chronic (repeated) whole-body heat exposure has been shown to increase NO bioavailability, decrease ET-1, and cause functional and structural adaptations in the vasculature. All these can improve vascular function, attenuate sympathetic (re)activity, lower blood pressure (BP), and reduce cardiovascular risk in non-pregnant individuals. Whether this is also true after regional (leg) heating in high-risk pregnant women is unknown. The investigators' central hypothesis is that chronic leg heating will be effective in improving vascular endothelial function and attenuating sympathetic vasoconstriction, leading to a reduction of the risk for HDP in pregnant women with obesity. The overarching goal of this proposal is to determine the vascular and neural effects of chronic leg heating in obese pregnancy. The study team plans to enroll pregnant women with obesity between 12-14 weeks of gestation and randomly assign them to either an intervention group or a control group (1:1 ratio). Participants in the intervention group will perform 16 weeks of home-based leg heating using a portable sauna blanket up to the hip (temperature of the blanket will be set at 65°C, 4 times\u002Fweek, 45 min\u002Fsession), whereas women in the control group will set the temperature of the blanket at 35°C at the same frequency and duration. Participants will be evaluated at baseline and then at 28-30 weeks of gestation. Aim 1 will determine the effects of chronic leg heating on maternal vascular function and surrogate markers of HDP. Aim 2 will determine the effects of chronic leg heating on sympathetic vasoconstriction and BP. Findings from this project will provide insight on the extent and potential mechanisms of how chronic leg heating works for improving vascular endothelial function and sympathetic vasoconstriction in pregnant women with obesity. Results obtained will set a foundation for future large multicenter clinical trials to determine the efficacy and generalizability of home-based leg heat therapy as a safe, ease-of-use, cost-effective, and non-drug approach for reducing the risk of HDP.",[66],"High-risk Pregnancy",[68,69,70,71,72,73],"Pregnancy","Obesity","Heat therapy","Vascular function","Sympathetic neural control","Blood pressure","RECRUITING","2026-04-15",{"date":77,"type":44},"2026-04-17",{"date":79,"type":44},"2025-08-01",{"date":81,"type":20},"2030-04-30",{"name":83,"class":51},"University of Texas Southwestern Medical Center",1,{"id":86,"slug":87,"hasResults":11,"nctId":88,"briefTitle":89,"officialTitle":90,"acronym":4,"eligibilityCriteria":91,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":92,"enrollmentInfo":93,"targetDuration":4,"studyType":21,"phases":95,"briefSummary":97,"conditions":98,"keywords":4,"overallStatus":74,"whyStopped":4,"lastUpdateSubmitDate":103,"lastUpdatePostDateStruct":104,"startDateStruct":106,"completionDateStruct":108,"leadSponsor":110,"locationsCount":112},"100297442","phase-2-impact-study-improve-pregnancy-in-aps-with-certolizumab-therapy-100297442","NCT03152058","IMPACT Study: IMProve Pregnancy in APS With Certolizumab Therapy","Certolizumab to Prevent Pregnancy Complications in High-Risk Patients With APS or SLE - (IMPACT Study: IMProve Pregnancy in APS With Certolizumab Therapy)","Inclusion Criteria:\n\n* Pregnant as defined by positive test for elevated ß-HCG and having a live, appropriate sized embryo by ultrasound, but \\\u003C8 weeks gestation;\n* Antiphospholipid syndrome (APS);\n* Positive for LAC on two or more occasions greater than 12 weeks apart within the previous 18 months. If a candidate for the study is newly diagnosed (\\\u003C12 weeks) with APS, meets clinical criteria for APS and has one positive LAC confirmed by review of the medical record, she may be consented and screened. At baseline, LAC will be measured at the study core lab and she will be enrolled if it is found to be positive. The LAC measurement will be repeated 12 weeks after the initial determination and, if positive, she will remain in the study.\n* Age 18-40 (+364 days) years of age and able to give informed consent\n* Laboratory hematocrit \\>26% at time of screening.\n\nthe diagnosis of APS and LAC will be confirmed by one of the Co-PI's for each case by a review of the medical records.\n\nExclusion Criteria:\n\n* Hypertension (BP \\>140\u002F90) present at screening;\n* Multifetal gestation;\n* Type 1 or Type 2 diabetes antedating pregnancy;\n* SLE patients requiring prednisone \\>10 mg\u002Fday;\n* Platelet count \\\u003C100,000 per microliter;\n* Women currently taking prednisone greater than 10 mg daily for an autoimmune disorder, other than immune thrombocytopenia;\n\n  a. More than 60 mg once daily in a tapering regimen or 20 mg once daily in a maintenance regimen for immune thrombocytopenia\n* Women with urinary excretion with greater than 500 mg (0.5 g) per day (spot urine protein\u002Fcreatinine ration 0.5);\n* Serum creatinine \\>1.2 mg\u002FdL\n* History of tuberculosis or untreated positive PPD;\n* Women with a tuberculin skin test induration of 5 mm or greater; or positive quantiFERON-gold test\n* Women with HIV, Hepatitis B or Hepatitis C positive status;\n* Known contraindications or relative contraindications to certolizumab:\n\n  1. Active infection, e.g., chronic hepatitis B\n  2. History of recurrent infection, e.g., recurrent cellulitis, or opportunistic infection\n  3. History of prior active\u002Ftreated endemic mycoses in the last two years (including coccidioidomycosis, blastomycosis, or histoplasmosis)\n  4. History of heart failure\n  5. History of peripheral demyelinating disease or Guillian-Barre syndrome\n  6. History of hematologic malignancy\n  7. Prior adverse reaction to certolizumab or o ther anti-TNF-α agent","40 Years",{"count":94,"type":20},55,[96],"PHASE2","This treatment trial evaluates the addition of an anti-tumor necrosis factor-alpha drug, certolizumab, to usual treatment (a heparin agent and low-dose aspirin) in pregnant women with antiphospholipid syndrome (APS) and repeatedly positive tests for lupus anticoagulant (LAC) to determine if this regimen will improve pregnancy outcomes. All enrolled patients will receive certolizumab, and pregnancy outcomes will be compared to those of women with APS and repeatedly positive tests for LAC enrolled in a previous study by the investigators.",[99,100,101,102],"High Risk Pregnancy","Pregnancy Complications","Antiphospholipid Syndrome in Pregnancy","Lupus Anticoagulant Disorder","2026-03-27",{"date":105,"type":44},"2026-04-01",{"date":107,"type":44},"2017-05-17",{"date":109,"type":20},"2027-12",{"name":111,"class":51},"David Ware Branch",3,{"id":114,"slug":115,"hasResults":11,"nctId":116,"briefTitle":117,"officialTitle":118,"acronym":4,"eligibilityCriteria":119,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":120,"targetDuration":4,"studyType":122,"phases":4,"briefSummary":123,"conditions":124,"keywords":128,"overallStatus":74,"whyStopped":4,"lastUpdateSubmitDate":131,"lastUpdatePostDateStruct":132,"startDateStruct":134,"completionDateStruct":136,"leadSponsor":138,"locationsCount":84},"100579295","remote-fetal-monitoring-in-high-risk-pregnancies-100579295","NCT06822439","Remote Fetal Monitoring in High Risk Pregnancies","Investigating the Acceptability and Feasibility of Remote Fetal Monitoring in a High Risk Obstetric Population","Inclusion Criteria:\n\n* Intrauterine pregnancy greater than 32 weeks gestation\n* Recommended for at least once weekly antenatal fetal testing by their obstetrician\n* English-speaking\n\nExclusion Criteria:\n\n* Under age 18 years of old\n* Non-english speaking",{"count":121,"type":20},50,"OBSERVATIONAL","Antenatal nonstress tests (NSTs) are performed to assess fetal health and are used as a cost-effective test that can be widely administered. However, an NST is operator-dependent due to the nature of Doppler ultrasound and is primarily performed in a clinic and hospital setting.\n\nThe ability to conduct a clinically valuable test at home would address access to care issues faced by numerous women in the United States and reduce the workload on healthcare clinicians facing a shortage of human resources.\n\nThis pilot study aims to assess the feasibility and acceptability of home NST monitoring in order to determine whether femomTM could be utilized as an adjunct to routine prenatal care.\n\nPatients with high risk pregnancies who are recommended to undergo at least once weekly at 32 weeks testing by the obstetrician will be recruited for participation in this study. Participants will be asked to perform three 30 minute monitoring sessions weekly starting at 32 weeks for 6 weeks.",[99,125,126,127],"Remote Patient Monitoring","Diabetes","Hypertension",[68,129,130],"Non invasive testing","Remote patient monitoring","2026-03-06",{"date":133,"type":44},"2026-03-09",{"date":135,"type":44},"2025-05-01",{"date":137,"type":20},"2027-01-01",{"name":139,"class":51},"Beth Israel Deaconess Medical Center",{"id":141,"slug":142,"hasResults":11,"nctId":143,"briefTitle":144,"officialTitle":145,"acronym":4,"eligibilityCriteria":146,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":147,"targetDuration":4,"studyType":122,"phases":4,"briefSummary":149,"conditions":150,"keywords":169,"overallStatus":74,"whyStopped":4,"lastUpdateSubmitDate":180,"lastUpdatePostDateStruct":181,"startDateStruct":183,"completionDateStruct":185,"leadSponsor":187,"locationsCount":189},"100345304","fetal-electrophysiologic-abnormalities-in-high-risk-pregnancies-associated-with-fetal-demise-100345304","NCT03775954","Fetal Electrophysiologic Abnormalities in High-Risk Pregnancies Associated With Fetal Demise","Fetal Electrophysiologic Abnormalities in High-risk Pregnancies Associated With Fetal Demise","Inclusion Criteria:\n\n* Current pregnancy complicated by one of the five diagnostic categories\n\n  * prior unexplained Stillbirth at\u002Fafter 20 weeks gestation\n  * fetal major congenital heart defect\n  * fetal hydrops\n  * fetal gastroschisis\n  * monochorionic twin pregnancy\n* Subject must be 18 years of age or older\n* Subject must be English speaking and must be able to read and sign the consent form in English\n* Subject must be able to recline comfortably for 1-3 hours\n* Subject must be willing to complete all three procedures (fMCG, fMCG, nECG) as per protocol, unless medically unable\n* Subject must be willing to allow us to review her and her infants prenatal, deliver, and post-natal records to verify diagnosis, and clinical findings.\n\nExclusion Criteria:\n\n* Severe claustrophobia not reduced by taking breaks, or by having the light on, or by having someone in the room with them.\n* Active labor\n* Acute illness\n* Unable to recline comfortably with a pillow for more than 1-3 hours (assuming some breaks are provided)\n* Weight over 450 lbs\n* An electric stimulation device (TENS unit, pacemaker, or nerve stimulator) that could produce electric or magnetic noise.\n\n  * Note that the Tristan 624 Magnetometer does not pose a risk to the subject's device, (since fMCG does not produce any energy or magnetism), but stimulators themselves can cause interference for our recordings. Some devices may still qualify, and discussion with study nurse may be useful if subject has a pacemaker or similar device.\n\nThe subject will have a single 2-3 hour fetal magnetocardiogram at approximately 20 and 27 weeks GA, and again, if medical condition allows, between 30 and 37 weeks GA, then her infant will have an ECG between 0 and 4 weeks of age. Subjects will be paid a nominal fee for their participation each time, as well as transportation reimbursement if \\>25 miles. For subjects traveling a long distance, the ECG may be performed locally or at home.",{"count":148,"type":20},30,"Each year world-wide, 2.5 million fetuses die unexpectedly in the last half of pregnancy, 25,000 in the United States, making fetal demise ten-times more common than Sudden Infant Death Syndrome. This study will apply a novel type of non-invasive monitoring, called fetal magnetocardiography (fMCG) used thus far to successfully evaluate fetal arrhythmias, in order to discover potential hidden electrophysiologic abnormalities that could lead to fetal demise in five high-risk pregnancy conditions associated with fetal demise.",[99,151,152,153,154,155,156,157,158,159,160,161,162,163,164,165,166,167,168],"Congenital Heart Disease","Fetal Hydrops","Twin Monochorionic Monoamniotic Placenta","Gastroschisis","Fetal Demise","Stillbirth","Fetal Arrhythmia","Long QT Syndrome","Intrauterine Fetal Death","Sudden Infant Death","Pregnancy Loss","Twin Twin Transfusion Syndrome","Birth Defect","Fetal Cardiac Anomaly","Fetal Cardiac Disorder","Fetal Death","Brugada Syndrome","Fetal Tachycardia",[170,156,171,172,173,99,68,174,175,176,177,178,179],"Fetal Magnetocardiography","Intrauterine Fetal Demise","Fetal Heart Rate Variability","Fetal Arrhythmias","Fetal Anomaly","Fetal Echocardiography","Non-Stress Testing","New Technology","Birth Defects","Fetal Research","2026-03-02",{"date":182,"type":44},"2026-03-04",{"date":184,"type":44},"2018-07-01",{"date":186,"type":20},"2028-11-30",{"name":188,"class":51},"Medical College of Wisconsin",2,{"id":191,"slug":192,"hasResults":11,"nctId":193,"briefTitle":194,"officialTitle":195,"acronym":4,"eligibilityCriteria":196,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":60,"enrollmentInfo":197,"targetDuration":4,"studyType":21,"phases":199,"briefSummary":200,"conditions":201,"keywords":4,"overallStatus":40,"whyStopped":4,"lastUpdateSubmitDate":204,"lastUpdatePostDateStruct":205,"startDateStruct":207,"completionDateStruct":208,"leadSponsor":210,"locationsCount":84},"100625527","tele-supported-motor-imagery-exercise-in-high-risk-pregnancy-100625527","NCT07423793","Tele-Supported Motor Imagery Exercise in High-Risk Pregnancy","Maternal and Fetal Effects of Tele-Rehabilitation-Supported Motor Imagery-Based Exercise in High-Risk Pregnancy: A Randomized Controlled Trial","Inclusion Criteria:\n\n1. Pregnant women who have completed the 12th week of gestation, are hospitalized for inpatient care, and have at least one of the following risk factors:\n\n   * Obstetric conditions associated with adverse outcomes and physical activity restriction, such as cervical insufficiency, multiple pregnancy, or uncontrolled gestational diabetes, for which exercise is contraindicated;\n   * Maternal body mass index (BMI) greater than 30 kg\u002Fm² leading to physical inactivity.\n2. Ability to read and write in Turkish.\n3. Willingness to participate voluntarily in the study.\n\nExclusion Criteria:\n\n1. Pregnant women with conditions such as gestational diabetes mellitus or pregnancy-induced hypertension for whom physical activity is recommended.\n2. Presence of severe cardiovascular, pulmonary, or systemic disorders.\n3. Presence of seizure disorders or significant psychiatric conditions.\n4. Any cognitive impairment that interferes with cooperation or understanding.\n5. Any medical condition that prevents safe and effective implementation of the interventions.\n6. Other high-risk obstetric conditions requiring early medical intervention (e.g., premature rupture of membranes, placenta previa, preeclampsia).\n\nLack of digital literacy required to participate in tele-rehabilitation.\n\n\\-",{"count":198,"type":20},38,[23],"High-risk pregnancy is defined as a pregnancy in which there is an increased likelihood of adverse maternal and\u002For fetal outcomes due to maternal or fetal conditions. The global prevalence of high-risk pregnancies ranges between 10% and 60%. In cases where pregnancy complications occur, bed rest is frequently recommended to prevent further deterioration. However, prolonged inactivity may lead to unfavorable maternal outcomes, and appropriately prescribed exercise may help reduce the negative consequences of immobility.\n\nLong-term maternal exercise has been shown to promote vascular remodeling and angiogenesis in the uterine and umbilical arteries, increase vessel diameter, and reduce vascular resistance. Previous studies have demonstrated that exercise reduces the risk of gestational diabetes, preeclampsia, gestational hypertension, and macrosomia without increasing the risk of preterm birth, low birth weight, or perinatal mortality. Despite these benefits, women with high-risk pregnancies may have different perceptions and concerns regarding physical activity compared to healthy pregnant women.\n\nMotor imagery is a mental process in which an individual cognitively rehearses a movement without performing it physically. Neuroimaging studies have demonstrated activation of similar brain regions during motor imagery and actual movement. Mental imagery-guided relaxation exercises have been shown to improve maternal anxiety, stress levels, fetal attachment, and blood pressure in both healthy and hypertensive pregnancies. Recent findings also indicate that motor imagery-based exercise combined with diaphragmatic breathing does not adversely affect the fetus in high-risk pregnancies and may improve maternal well-being and oxygen saturation without inducing uterine contractions.\n\nThis randomized controlled trial aims to investigate the maternal and fetal effects of an 8-week tele-rehabilitation-supported motor imagery-based exercise program in high-risk pregnant women who are prescribed hospital- or home-based bed rest.",[99,202,203],"Tele-rehabilitation","Mental Imagery","2026-02-15",{"date":206,"type":44},"2026-02-20",{"date":206,"type":20},{"date":209,"type":20},"2027-02-28",{"name":211,"class":51},"Izmir University of Economics",{"id":213,"slug":214,"hasResults":11,"nctId":215,"briefTitle":216,"officialTitle":216,"acronym":4,"eligibilityCriteria":217,"healthyVolunteers":59,"sex":218,"minAge":219,"maxAge":4,"enrollmentInfo":220,"targetDuration":222,"studyType":122,"phases":4,"briefSummary":223,"conditions":224,"keywords":225,"overallStatus":74,"whyStopped":4,"lastUpdateSubmitDate":230,"lastUpdatePostDateStruct":231,"startDateStruct":233,"completionDateStruct":235,"leadSponsor":237,"locationsCount":84},"100441959","ucla-perinatal-biospecimen-repository-100441959","NCT05035160","UCLA Perinatal Biospecimen Repository","Inclusion Criteria:\n\n* Pregnant and postpartum birthing persons aged 18 and over with perinatal pathology;\n* Healthy pregnant and postpartum birthing persons;\n* Healthy non-pregnant birthing persons (healthy volunteers).\n\nExclusion Criteria:\n\n* Pregnant and postpartum birthing person unwilling to give written informed consent to participate in the study.","ALL","1 Minute",{"count":221,"type":20},1000,"5 Years","The purpose of this investigator-initiated prospective observational cohort study is to establish the new UCLA Perinatal Biospecimen Repository (Perinatal Repository) for collection, storage, and distribution of the human data and biospecimens of the participants with perinatal pathology. The secure and shared high-quality resource of clinical data and biological specimens (Repository Materials), across pregnancy pathology related to research protocols at the Afshar's Lab will be created. Core variables of interest include clinical characteristics and relevant biological samples. Intention to collect perinatal data is aiding the efficiency and effectiveness of de-identified biorepository for pregnancy-at-risk outcome research.\n\nThe primary aims of the project are:\n\n* To design the Case Report Forms (CRFs) for the clinical and biospecimen data.\n* To create and update the project-specific policies, agreements, and Standard Operating Procedures (SOPs).\n* To develop the data management system to assure personal health information de-identification, data integrity, participants welfare, and protocol compliance.\n* To develop and implement a quality management system for the Repository.\n* To collect and record in the Repository protocol-related clinical information.\n* To organize a consistent system to bank high-quality biospecimens while protecting participant-donor safety and privacy.\n* To establish the policies and procedures for Repository Materials dissemination and research collaboration.\n* To analyze the scientific results of the Repository creation. The secondary aim of the study is to provide a mechanism to store and share for research purposes the de-identified biospecimen and information about participants at risk for adverse pregnancy outcomes.",[68,28],[226,227,228,68,229],"Fetus","Obstetrics","Perinatal Care","Specimen Collection","2025-12-19",{"date":232,"type":44},"2025-12-29",{"date":234,"type":44},"2021-07-30",{"date":236,"type":20},"2028-12-31",{"name":238,"class":51},"Yalda Afshar, MD, PhD",{"id":240,"slug":241,"hasResults":11,"nctId":242,"briefTitle":243,"officialTitle":244,"acronym":4,"eligibilityCriteria":245,"healthyVolunteers":59,"sex":16,"minAge":4,"maxAge":4,"enrollmentInfo":246,"targetDuration":4,"studyType":21,"phases":248,"briefSummary":249,"conditions":250,"keywords":252,"overallStatus":74,"whyStopped":4,"lastUpdateSubmitDate":257,"lastUpdatePostDateStruct":258,"startDateStruct":260,"completionDateStruct":262,"leadSponsor":264,"locationsCount":84},"100614572","effect-of-hypnobreastfeeding-education-in-high-risk-pregnant-women-100614572","NCT07281339","Effect of Hypnobreastfeeding Education in High-Risk Pregnant Women","The Effect of Hypnobreastfeeding Education Given to High-Risk Pregnant Women on Anxiety Levels, Infant Feeding Intention, Postpartum Perception of Insufficient Milk, and Breastfeeding Adaptation","Inclusion Criteria:\n\n* High-risk primiparous pregnant women\n* Those with 28-34 weeks of pregnancy\n* Those who volunteered to participate in the study\n* Those who can read and write Turkish\n\nExclusion Criteria:\n\n* Those with communication disabilities\n* Those with psychiatric and mental illnesses\n* Those who have an obstacle to breastfeeding\n* Those who have previously attended a birth preparation class\n* Those who receive breastfeeding-related training and consultancy\n* Those who gave birth prematurely\n* Those with anomalies in their babies",{"count":247,"type":20},68,[23],"It is thought that hypnobreastfeeding training given to high-risk pregnant women will reduce anxiety levels, increase lactation, encourage breastfeeding, reduce the perception of insufficient milk, and facilitate adaptation to the postpartum breastfeeding process. According to the results of the power analysis, at least 68 high-risk pregnant women, 34 experimental and 34 control, should be included in the study. Data will be collected with the \"Pregnancy Information Form\", \"Anxiety Assessment Scale\", \" Infant Feeding Intention Instrument\", \"Postpartum Information Form\", \"Perception of Insufficient Milk Questionnaire\" and \"Breastfeeding Adaptation Scale\". In the research, hypnobreastfeeding training will be applied by the researcher to the high-risk pregnant women in the experimental group.",[66,251],"Breast Feeding",[253,34,254,255,256],"Hypnobreastfeeding","Infant Feeding Intention","Perception of Insufficient Milk","Breastfeeding Adaptation","2025-12-01",{"date":259,"type":44},"2025-12-15",{"date":261,"type":44},"2025-10-15",{"date":263,"type":20},"2026-06-30",{"name":265,"class":51},"Amasya University",{"id":267,"slug":268,"hasResults":11,"nctId":269,"briefTitle":270,"officialTitle":271,"acronym":272,"eligibilityCriteria":273,"healthyVolunteers":59,"sex":16,"minAge":274,"maxAge":275,"enrollmentInfo":276,"targetDuration":4,"studyType":21,"phases":278,"briefSummary":279,"conditions":280,"keywords":282,"overallStatus":40,"whyStopped":4,"lastUpdateSubmitDate":292,"lastUpdatePostDateStruct":293,"startDateStruct":295,"completionDateStruct":297,"leadSponsor":298,"locationsCount":84},"100590958","ai-powered-cura-application-for-identifying-at-risk-pregnancies-in-obstetric-management-100590958","NCT06974188","AI-Powered CURAᵀᴹ Application for Identifying At-Risk Pregnancies in Obstetric Management","AI-Powered CURAᵀᴹ Application for Identifying At-Risk Pregnancies in Obstetric Management: A Randomized Controlled Trial (CURAte)","CURAte","Inclusion Criteria:\n\n* Age: 21 years old to 50 years old\n* Singleton Pregnancy\n* No more than 13 weeks' and 6 days' gestation at recruitment\n* Able to provide written, informed consent\n\nExclusion Criteria:\n\n* Not proficient in the English language (AI intervention is only available in English at this stage)","21 Years","50 Years",{"count":277,"type":20},1700,[23],"It is important to identify high pregnancies early through screening so that appropriate care and intervention may be instituted. An AI-assisted risk categorisation approach may be advantageous compared with traditional means of screening. The purpose of this study is to determine if the adoption of an AI-assisted approach in general pregnancy risk screening will improve the accuracy of antenatal risk categorization into high- and low- risk pregnancy groups, ultimately resulting in fewer poor maternal and fetal\u002Fneonatal outcomes.",[66,68,281],"Antenatal Health",[283,284,285,286,287,100,288,289,290,291],"Machine-learning","Artificial Intelligence","Antenatal Risk Stratification","Software as a Medical Device","Machine Learning Algorithm","Neonatal Complications","Pregnancy outcomes","Obstetric complications","Antenatal care","2025-07-14",{"date":294,"type":44},"2025-07-15",{"date":296,"type":20},"2025-08",{"date":48,"type":20},{"name":299,"class":51},"National University Hospital, Singapore",{"id":301,"slug":302,"hasResults":11,"nctId":303,"briefTitle":304,"officialTitle":305,"acronym":306,"eligibilityCriteria":307,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":308,"targetDuration":4,"studyType":122,"phases":4,"briefSummary":310,"conditions":311,"keywords":4,"overallStatus":74,"whyStopped":4,"lastUpdateSubmitDate":314,"lastUpdatePostDateStruct":315,"startDateStruct":317,"completionDateStruct":319,"leadSponsor":321,"locationsCount":84},"100422651","early-prediction-of-preeclampsia-using-arterial-stiffness-in-high-risk-pregnancies-100422651","NCT04783597","Early Prediction of Preeclampsia Using arteriaL Stiffness in High-risk prEgnancies","Early Prediction of Preeclampsia Using arteriaL Stiffness in High-risk prEgnancies; a Multinational Study (PULSE)","PULSE","Inclusion Criteria:\n\n* Singleton pregnancy\n* Presence of at least 1 high-risk factor or 2 moderate-risk factors for pre-eclampsia\n\nExclusion Criteria:\n\n* \\>14 weeks gestation\n* Multiple pregnancy\n* History of heart disease, stroke, or peripheral arterial disease\n* Infectious diseases\u002Fconditions, such as Hepatitis B\u002FC, HIV, and COVID19",{"count":309,"type":20},2400,"Despite advances in obstetric care, preeclampsia (PE) remains the leading cause of maternal death and disability in both developed and developing countries, contributing to over 70,000 maternal and 500,000 fetal deaths annually worldwide. PULSE was designed using a preventative medicine approach, focusing on improving early detection of PE as opposed to managing symptoms after onset. The study aims to uncover the earliest possible signs of PE using a combination of novel clinical tools and established diagnostic techniques to better identify, track, and manage high risk pregnant women. Specifically, PULSE will be examining the incorporation of a non-invasive test for the measurement of arterial stiffness, which has been shown to be predictive of hypertensive disorders. This test, in combination with a wide range of blood biomarkers, detailed ultrasound imaging, and a comprehensive battery of physical and mental health questionnaires, represents the largest, most comprehensive preventative PE study to date. The results of this work has the potential to revolutionize the way PE and other hypertensive disorders of pregnancy are managed and treated and can serve to inform the design of future preventative clinical research studies.",[99,312,313],"Arterial Stiffness","Pre-Eclampsia","2025-04-15",{"date":316,"type":44},"2025-04-18",{"date":318,"type":44},"2021-07-12",{"date":320,"type":20},"2027-01",{"name":322,"class":51},"McGill University Health Centre\u002FResearch Institute of the McGill University Health Centre",{"id":324,"slug":325,"hasResults":11,"nctId":326,"briefTitle":327,"officialTitle":327,"acronym":328,"eligibilityCriteria":329,"healthyVolunteers":59,"sex":16,"minAge":17,"maxAge":60,"enrollmentInfo":330,"targetDuration":4,"studyType":122,"phases":4,"briefSummary":332,"conditions":333,"keywords":4,"overallStatus":74,"whyStopped":4,"lastUpdateSubmitDate":340,"lastUpdatePostDateStruct":341,"startDateStruct":343,"completionDateStruct":345,"leadSponsor":347,"locationsCount":349},"100547951","multicenter-prospective-cohort-study-of-twin-maternal-child-dyads-in-china-100547951","NCT06414655","Multicenter Prospective Cohort Study of Twin Maternal-Child Dyads in China","ChiTwiMC","Inclusion Criteria:\n\n* Twin pregnancies\n* Female aged between 18-45 years\n* Gestational age is less than 14 weeks\n* Planning to receive prenatal healthcare and delivery service at the study hospital\n* Signing informed concent and willing to participate\n\nExclusion Criteria:\n\n* Women with mental disorders or serious maternal illness that is not eligible to participate\n* Inability to provide informed consent\n* Pregnant women not registered in our hospital",{"count":331,"type":20},2000,"Multicenter Prospective Cohort Study of Twin Maternal-Child Dyads in China (ChiTwiMC) is supported by National Key Research and Development Program of China - Reproductive Health and Women's and Children's Health Protection Project. This project is funded by the Ministry of Science and Technology of China under grant number 2023YFC2705900. The ChiTwiMC cohort is led by Professor Wei Yuan from the Department of Gynecology and Obstetrics at Peking University Third Hospital.",[334,335,336,313,337,338,99,339],"Twin Pregnancy, Antepartum Condition or Complication","Twin to Twin Transfusion as Antepartum Condition","Pre-Term","Twin Monochorionic Diamniotic Placenta","Twin Dichorionic Diamniotic Placenta","Twin Placenta","2024-05-09",{"date":342,"type":44},"2024-05-16",{"date":344,"type":44},"2024-03-01",{"date":346,"type":20},"2026-11-30",{"name":348,"class":51},"Peking University Third Hospital",11,{"id":351,"slug":352,"hasResults":11,"nctId":353,"briefTitle":354,"officialTitle":355,"acronym":4,"eligibilityCriteria":356,"healthyVolunteers":59,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":357,"targetDuration":4,"studyType":21,"phases":359,"briefSummary":360,"conditions":361,"keywords":4,"overallStatus":40,"whyStopped":4,"lastUpdateSubmitDate":362,"lastUpdatePostDateStruct":363,"startDateStruct":365,"completionDateStruct":367,"leadSponsor":369,"locationsCount":4},"100334645","verify-the-safety-and-effectiveness-of-the-cerclage-pessary-in-prevention-and-treatment-of-high-risk-preterm-pregnancy-100334645","NCT03637062","Verify the Safety and Effectiveness of the Cerclage Pessary in Prevention and Treatment of High-risk Preterm Pregnancy","Verify the Safety and Effectiveness of the Cerclage Pessary in the Prevention and Treatment of High-risk Preterm Pregnancy","Inclusion Criteria:\n\n* Women with a pregnancy and a history of at least one spontaneous preterm birth before 34+0 weeks and\u002For a history of late abortion\n* 12+0 -18+0 weeks of gestation\n* Minimal age of 18 years\n* Informed consent signature\n\nExclusion Criteria:\n\n* The previous preterm delivery is iatrogenic proterm labor\n* Major fetal abnormalities (requiring surgery or leading to infant death or severe handicap)\n* The pregnant woman with severe cervical erosion, cervical polyp, hemorrhage and the doctors think she could not use cerclage pessary\n* The pregnant woman with uterine cervicitis\n* The pregnant woman that has been confirmed premature birth\n* Cerclage prior to randomisation\n* Cerclage prior to randomisation\n* Placenta previa totalis\n* Active vaginal bleeding at the moment of randomization\n* Spontaneous rupture of membranes at the time of randomization\n* Silicone allergy\n* Painful regular uterine contractions\n* The pregnant woman have the indication of operation cervical cerclage\n* Current participation in other RCT",{"count":358,"type":20},300,[23],"Verify the safety and effectiveness of the cerclage pessary in the prevention and treatment of high-risk preterm pregnancy.",[99],"2023-11-14",{"date":364,"type":44},"2023-11-18",{"date":366,"type":20},"2024-12-01",{"date":368,"type":20},"2026-12-01",{"name":370,"class":51},"QH Medical Technology Ltd."]